

# Ohad Oren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9431744/publications.pdf>

Version: 2024-02-01

21  
papers

358  
citations

1478280

6  
h-index

1058333

14  
g-index

21  
all docs

21  
docs citations

21  
times ranked

460  
citing authors

#	ARTICLE	IF	CITATIONS
1	Artificial intelligence in medical imaging: switching from radiographic pathological data to clinically meaningful endpoints. <i>The Lancet Digital Health</i> , 2020, 2, e486-e488.	5.9	128
2	Curbing Unnecessary and Wasted Diagnostic Imaging. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 245.	3.8	64
3	Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2020, 22, 66.	1.8	59
4	Cardiovascular Health and Outcomes in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>American Journal of Cardiology</i> , 2020, 125, 1920-1926.	0.7	50
5	Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2020, 13, e008688.	2.1	17
6	Incidental Imaging Findings in Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 603.	3.8	9
7	On the Pearls and Perils of Sub-Subspecialization. <i>American Journal of Medicine</i> , 2020, 133, 158-159.	0.6	6
8	Anticipating and curtailing the cardiometabolic toxicity of social isolation and emotional stress in the time of COVID-19. <i>American Heart Journal</i> , 2020, 226, 1-3.	1.2	6
9	Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience). <i>American Journal of Cardiology</i> , 2019, 124, 1669-1673.	0.7	5
10	Addressing Imaging Pitfalls to Reduce Cardiovascular Disease Misdiagnosis in Patients With Breast Cancer Following Reconstruction. <i>JAMA Cardiology</i> , 2022, 7, 123.	3.0	5
11	Cardiovascular Safety Assessment in Cancer Drug Development. <i>Journal of the American Heart Association</i> , 2021, 10, e024033.	1.6	5
12	Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Disease. <i>Current Oncology Reports</i> , 2020, 22, 87.	1.8	2
13	Cost-Effectiveness Analyses of FDA-Approved Drugs for Cancer Indications, 2015-2017. <i>Blood</i> , 2018, 132, 5833-5833.	0.6	1
14	No Diagnostic Concerns With Cardiovascular Magnetic Resonance Imaging in Patients With Breast Cancer and Breast Implants—Reply. <i>JAMA Cardiology</i> , 2022, 7, 655.	3.0	1
15	Solutions to Reduce Unnecessary Imaging—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 2243.	3.8	0
16	Cardiovascular Prevention in Individuals at High Risk of Developing Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 527-531.	1.7	0
17	Recognizing “diagnostic futility”—stopping earlier to protect patients. <i>American Journal of Hematology</i> , 2020, 95, 580-582.	2.0	0
18	Improving Communication of Incidental Imaging Findings. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2753-2756.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Drug Value Along the Treatment Continuum in Hodgkin Lymphoma. Blood, 2018, 132, 4728-4728.	0.6	0
20	Investigation-Based Drug Value Framework in Hodgkin Lymphoma. Blood, 2018, 132, 2262-2262.	0.6	0
21	Geographic Trends in Clinical Trials in Lymphoma, 1997-2017. Blood, 2018, 132, 3554-3554.	0.6	0